Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Calithera Biosciences, Inc
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. Newly diagnosed patients who refuse standard treatment regimens are also eligible
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Life Expectancy of at least 3 months
Adequate hepatic, renal, cardiac, and hematologic function
Measurable disease by RECIST criteria
Ability to provide written informed consent in accordance with federal, local, and institutional guidelines
You may not be if
Any other current or previous malignancy
Chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within 21 days
Unable to receive medications oral medications
Major surgery within 28 days before Cycle 1 Day 1
Active infection requiring within 2 weeks prior to first dose of study drug
Patients who have HIV, Hepatitis A, B or C or CMV reactivation
Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose of study drug
Conditions that could interfere with treatment or protocol-related procedures
